HCPCS Code J2260: Injection, milrinone lactate, 5 mg

Key takeaways

HCPCS Code J2260 covers injection of milrinone lactate, 5 mg, billed as one unit per 5 mg administered.

Medicare Part B pays J2260 at ASP plus 6%. Rates change every quarter, so check the current CMS ASP file before you bill.

NDC reporting is required by most payers. A missing NDC or the wrong package size is the most common denial trigger for J2260.

Practice management software like Pabau supports J-code claim submission, tracking, and remittance reconciliation in one billing workflow.

HCPCS Code J2260 is the HCPCS Level II code for injection of milrinone lactate, 5 mg. One unit covers 5 mg of drug administered, so the unit count on the claim follows the documented dose. Milrinone appears infrequently in outpatient cardiology, and the buy-and-bill mechanics behind it are unfamiliar to many coders.

This reference covers the code definition, Medicare Part B coverage, ASP pricing, NDC crosswalk requirements, billing guidelines, and the errors that trigger denials.

HCPCS Code J2260: definition and code status

HCPCS Code J2260 is the CMS Level II HCPCS code for injection of milrinone lactate, 5 mg. Each unit of J2260 represents exactly 5 mg of milrinone lactate administered by injection. The code is active and billable for calendar years 2025 and 2026.

Clinical overview: what is milrinone lactate?

Milrinone lactate is a phosphodiesterase III (PDE3) inhibitor and inotropic agent. It is used for the short-term management of acute decompensated congestive heart failure. The drug increases cardiac contractility and reduces vascular resistance, which helps patients who respond poorly to standard heart failure therapy.

Because it requires intravenous administration and careful hemodynamic monitoring, milrinone is almost always given in a supervised clinical setting. Most clinical guidelines do not support chronic outpatient use.

Its appearance on a claim signals a high-acuity cardiac patient, which Medicare and commercial payers treat as requiring documented medical necessity. Without a clear record of the clinical indication and the administered dose, denial is likely.

• Drug class: Phosphodiesterase III inhibitor / inotropic agent
• Primary indication: Acute decompensated congestive heart failure (CHF)
• Route of administration: Intravenous injection or continuous infusion
• Formulations billed under J2260: Milrinone lactate injection and milrinone in 5% dextrose
• Monitoring requirement: Hemodynamic monitoring typically required during administration

Medicare coverage and J2260 Medicare reimbursement

Medicare Part B covers HCPCS Code J2260 when milrinone is administered as a physician-administered drug in an outpatient setting. Coverage depends on medical necessity, so the claim must be supported by the patient’s diagnosis, the indication for the drug, and the administered dose.

Medicare Administrative Contractors issue Local Coverage Determinations (LCDs) that define the coverage criteria in each jurisdiction. Check the applicable MAC policy before billing, because the documentation an LCD expects varies.

J2260 payment follows the ASP model rather than a fixed fee. Under Medicare Part B, physician-administered drugs are reimbursed at the Average Sales Price (ASP) plus 6%. CMS updates the ASP Drug Pricing File quarterly, so the reimbursement rate for J2260 changes four times per year.

J2260 fee schedule and ASP pricing

The J2260 payment rate is not a fixed annual figure. Because it is tied to the ASP+6% methodology, it moves with manufacturer pricing and the CMS quarterly update. To check the current amount, open the Medicare Part B ASP drug pricing files. Look up HCPCS code J2260 in the file for the current quarter.

For practices billing J2260 often, tracking ASP changes across quarters matters for cost accounting. A 10 mg dose reimbursed at one ASP rate in the first quarter may pay differently in the third. Build a quarterly review of the ASP file into your revenue cycle calendar to avoid revenue leakage.

Buy and bill: how J2260 billing works

Under Medicare Part B, J2260 follows the buy-and-bill model for physician-administered drugs. The practice purchases the drug, administers it, and then bills the payer to recover the cost plus reimbursement. The distance between acquisition cost and the ASP+6% payment rate decides whether the practice earns a margin or absorbs a loss.

The billing sequence for a buy-and-bill J2260 claim runs as follows:

1. Drug acquisition: Purchase milrinone lactate from a contracted supplier or wholesaler at or below ASP.
2. Administration and documentation: Administer the drug, document the dose in mg, route, date, clinical indication, and supervising provider.
3. Unit calculation: Divide the total administered dose in mg by 5 to determine the number of J2260 units. A 10 mg dose = 2 units; a 20 mg dose = 4 units.
4. NDC reporting: Record the NDC of the specific product vial used, the package size, and the administered quantity.
5. Claim submission: Submit J2260 with the calculated unit count and the NDC on the claim line. Add the supporting diagnosis code, typically a CHF ICD-10 code.
6. Remittance reconciliation: Review the electronic remittance advice to confirm payment at the expected ASP+6% rate.

NDC codes associated with J2260

The NDC (National Drug Code) crosswalk is a mandatory component of J2260 claims for most payers, including Medicare. The NDC identifies the drug product, manufacturer, and package size administered. Because several manufacturers supply milrinone lactate, the NDC on the claim must match the vial pulled from your dispensing inventory.

According to available product data, manufacturers currently supplying milrinone lactate products that map to J2260 include Pfizer, Fresenius Kabi, and Baxter. That list changes with manufacturing contracts and supply availability. Verify each mapping against the current ASP NDC-HCPCS crosswalk file, which CMS publishes quarterly alongside the ASP pricing file.

When reporting NDCs on a CMS-1500 form, place the NDC in box 24, line A, following the N4 qualifier. On electronic 837P claims, NDC information goes in the drug identification segment (LIN, CTP, and MEA loops). Your billing team should confirm the format requirements with your clearinghouse or the payer’s EDI companion guide.

Billing and coding guidelines for J2260

A clean J2260 claim depends on what the clinical record captures at the point of administration. Document the drug name, the dose in mg, the administration route, the date, and the supervising provider. The claim also needs a diagnosis drawn from the ICD-10-CM codes that support medical necessity for milrinone.

Without those elements, the claim lacks the medical necessity support that Medicare and most commercial payers require.

Units of service calculation

J2260 is billed per 5 mg. Divide the total administered milrinone dose by 5 to determine the correct unit count, then round to the nearest whole unit and document the calculation. Billing more units than the dose supports is an overcoding error, and billing fewer leaves reimbursement on the table.

The conversion below covers the doses this article works through, so you can check a unit count at a glance.

Example: a patient receives 20 mg of milrinone lactate. That is 20 divided by 5 = 4 units of J2260.

Common billing errors and how to avoid them

J2260 denials cluster around a handful of mistakes. Knowing them upfront prevents most of the rework that drives up denial management costs for cardiology and infusion practices.

• Wrong unit count: Billing one unit regardless of the administered dose is the single most common J2260 error. Always calculate units from the documented dose.
• Missing or incorrect NDC: Submitting J2260 without the NDC, or with a generic placeholder NDC, triggers an automatic denial from Medicare and many commercial payers. Pull the NDC from the vial administered.
• Modifier errors: Medicare requires JW when a single-dose container leaves discarded drug that you bill separately. Since July 2023 it also requires JZ, the attestation that no drug was discarded. One of the two belongs on every single-dose container claim.
• Missing diagnosis linkage: The claim line for J2260 must link to a diagnosis code that supports medical necessity for milrinone. An unspecified or unrelated cardiac code will not satisfy LCD requirements.
• Using the wrong formulation code: Milrinone in 5% dextrose (a pre-mixed bag formulation) is still billed under J2260. Some billers search for a separate code for this formulation. There is none, because J2260 covers both formulations.

Payer-specific coverage for J2260

Coverage rules for J2260 vary by payer and jurisdiction. Medicare Administrative Contractors may hold different LCD policies, and commercial plans often add prior authorization requirements that Medicare does not impose. Before administering milrinone in any setting, confirm coverage and authorization with the specific payer.

For a Medicare-enrolled patient, that check includes Part B injectable drug benefits, not only the office visit.

For commercial payers, obtain written authorization before administering milrinone outside an inpatient setting. Document the authorization number on the claim and in the patient chart before the infusion begins.

Related HCPCS codes to J2260

When billing for cardiac and cardiovascular injectable drugs alongside milrinone, coders frequently need adjacent J-codes. The table below covers the most commonly paired codes. For a broader search of injectable drug codes, use the AAPC HCPCS code lookup.

Streamlining J2260 claims with Pabau

Practices billing injectable drugs like milrinone usually capture the dose, the NDC, and the unit count on paper first, then retype them into the claim. Every retype is a chance for the unit count to drift away from the documented dose.

Pabau’s claims management software keeps claim submission, status tracking, and remittance reconciliation in one workflow next to the patient record. Validation covers claim fields such as membership numbers and authorization codes. Your coders still own the J2260 unit count and the NDC on the claim line.

For cardiology and infusion practices handling Part B drug billing, that means fewer places for a claim to stall between administration and payment. Book a demo to see how the workflow handles injectable drug claims.

Simplify injectable drug billing with Pabau

Pabau’s claims management tools help practices submit J-code claims, track their status, and reconcile remittances in one workflow. See how Pabau supports your billing team.

Book a demo

Conclusion

J2260 is a low-volume code with high-cost consequences. Two habits prevent most of its denials. Calculate the units from the documented dose every time, and pull the NDC from the vial you administered.

The quarterly ASP cycle is the part practices underestimate. Milrinone bought above the current ASP turns a clean claim into a loss, so the review calendar matters as much as the coding. Book a demo to see how Pabau keeps injectable drug claims moving from administration to payment.

Continue your research

Need a framework for reducing claim denials across your practice? Denial management in healthcare covers the systematic approach to preventing, tracking, and appealing payer rejections.

Want to understand how injectable drug claims fit into the broader billing cycle? What is revenue cycle management explains the end-to-end process from charge capture to payment posting.

Looking to tighten your documentation before claim submission? Superbill documentation outlines what needs to be captured at the point of care to support a clean claim.

Frequently asked questions